Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?

Lancet

Volumn 349, Issue 9070, 1997, Pages 29-30

  Nordin, Conny ^a   Dahl, Marja Liisa ^b   Eriksson, Mats ^b   Sjöberg, Stefan ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYTOCHROME P450; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; DNA POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; LETTER; MALE; PRIORITY JOURNAL;

EID: 0031008770     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(05)66238-1     Document Type: Article

References (5)

1. Vickers S, Duncan C, Chen I, et al. Metabolic disposition studies on simvastatin, a cholesterol lowering prodrug. Drug Metabol Dispos 1990; 18: 138-45.
2. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24: 195-202.
3. Eriksson M, EklundhT, Sjöberg S, et al. Cholesterol lowering and cerebrospinal fluid neurotransmitters: increased levels of anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers. Biol Psychiat 1996; 40: 302-04.
4. Mahgoub A, Idle J, Dring L, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; ii: 584-86.
5. Dahl M-L, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exper Ther 1995; 274: 516-20.